FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
SYDNEY, Nov. 9, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that an Investigational New Drug application (IND) for a trial of PXS-5505 in hepatocellular carcinoma (HCC) patients has been cleared by the United States Food and Drug Administr...
Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial
SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at t...
Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial
* Topical treatment safe and well tolerated in study of healthy volunteers * Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic exposure * Collaboration with research team led by Professor Fiona Wood AM planning for trial in patients with established scars to com...
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
SYDNEY, Aug. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBP...
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
* Boehringer Ingelheim commences Phase II program of investigational drug candidate BI 1467335 acquired from Pharmaxis with a 12 week Phase IIa proof of clinical principle study in non-alcoholic steatohepatitis (NASH) * New study underscores Boehringer Ingelheim's aspiration to deliver more ...
Boehringer Ingelheim Acquires Pharmaxis' Phase 1 Anti-inflammatory Drug Candidate
FRENCHS FOREST, Australia and INGELHEIM, Germany, May 18, 2015 /PRNewswire/ -- * Boehringer Ingelheim exercises option and acquires global ownership of Pharmaxis' investigational anti-inflammatory drug candidate PXS4728A, including associated intellectual property rights. * PXS4728A is a hig...